{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-067012","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.968137+00:00","generated_at":"2026-06-11T10:41:32.327227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q2 revenue falls 1% to $13.8M, GAAP EPS loss $(0.24), cuts 2023 outlook.","bullets":["Revenue $13.8M, down 1% YoY; gross profit $7.8M, down 13%.","GAAP net loss $(4.2)M ($(0.24)/share); non-GAAP net loss $(0.2)M ($(0.01)/share).","Repurchased 526,999 shares at avg $14.27 for $7.5M in Q2.","RWD.AI-enabled business saw 186% YoY growth in H1 2023.","Full-year 2023 revenue guidance cut to mid-$50s to low-$60s million; gross margin 55-59%."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-067012","json":"https://secwatch.observer/filing/0001213900-23-067012.json","markdown":"https://secwatch.observer/filing/0001213900-23-067012.md","text":"https://secwatch.observer/filing/0001213900-23-067012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/ea183450-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:41:32.327227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0744000b7477a435ffe8de20a0acd4a200254c0d","claim":"OptimizeRx Corp reported fiscal year 2023 results: revenue mid-50 to low-60 million dollars.","evidence_excerpt":"Based on first half results, the Company is updating its full year financial outlook for 2023. Revenues are now expected to be in the mid-50 to low-60 million dollar range with a gross margin rate between 55% and 59%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"mid-50 to low-60 million dollars"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6078fe7b67cbd18ba03c58bcf45401f93ef9c2ae","claim":"OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).","evidence_excerpt":"Revenue in the second quarter of 2023 decreased 1% to $13.8 million, as compared to $14.0 million in the same year ago period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"$(4.2) million"},{"label":"EPS","value":"$(0.24)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6078fe7b67cbd18ba03c58bcf45401f93ef9c2ae","claim":"OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).","evidence_excerpt":"GAAP net loss totaled $(4.2) million or $(0.24) per basic and diluted shares outstanding in the second quarter, as compared to $(3.9) million or $(0.21) during the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"$(4.2) million"},{"label":"EPS","value":"$(0.24)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}